364 related articles for article (PubMed ID: 12671778)
1. Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy.
Leitch H; Trudeau M; Routy JP
HIV Clin Trials; 2003; 4(2):107-14. PubMed ID: 12671778
[TBL] [Abstract][Full Text] [Related]
2. Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy.
Martinez V; Caumes E; Gambotti L; Ittah H; Morini JP; Deleuze J; Gorin I; Katlama C; Bricaire F; Dupin N
Br J Cancer; 2006 Apr; 94(7):1000-6. PubMed ID: 16570046
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda.
Asiimwe F; Moore D; Were W; Nakityo R; Campbell J; Barasa A; Mermin J; Kaharuza F
HIV Med; 2012 Mar; 13(3):166-71. PubMed ID: 22112164
[TBL] [Abstract][Full Text] [Related]
4. [HIV protease inhibitors for the treatment of Kaposi's sarcoma].
Grosso G; Sgadari C; Barillari G; Toschi E; Bacigalupo I; Carlei D; Palladino C; Baccarini S; Malavasi L; Moracci G; Leone P; Chiozzini C; Monini P; Ensoli B
Recenti Prog Med; 2003 Feb; 94(2):69-74. PubMed ID: 12908373
[TBL] [Abstract][Full Text] [Related]
5. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
[TBL] [Abstract][Full Text] [Related]
6. Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement.
Grabar S; Abraham B; Mahamat A; Del Giudice P; Rosenthal E; Costagliola D
J Clin Oncol; 2006 Jul; 24(21):3408-14. PubMed ID: 16849755
[TBL] [Abstract][Full Text] [Related]
7. Excellent clinical outcomes and retention in care for adults with HIV-associated Kaposi sarcoma treated with systemic chemotherapy and integrated antiretroviral therapy in rural Malawi.
Herce ME; Kalanga N; Wroe EB; Keck JW; Chingoli F; Tengatenga L; Gopal S; Phiri A; Mailosi B; Bazile J; Beste JA; Elmore SN; Crocker JT; Rigodon J
J Int AIDS Soc; 2015; 18(1):19929. PubMed ID: 26028156
[TBL] [Abstract][Full Text] [Related]
8. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy.
Pellet C; Chevret S; Blum L; Gauvillé C; Hurault M; Blanchard G; Agbalika F; Lascoux C; Ponscarme D; Morel P; Calvo F; Lebbé C
J Invest Dermatol; 2001 Oct; 117(4):858-63. PubMed ID: 11676823
[TBL] [Abstract][Full Text] [Related]
9. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma.
Tulpule A; Groopman J; Saville MW; Harrington W; Friedman-Kien A; Espina BM; Garces C; Mantelle L; Mettinger K; Scadden DT; Gill PS
Cancer; 2002 Jul; 95(1):147-54. PubMed ID: 12115328
[TBL] [Abstract][Full Text] [Related]
10. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome.
Cattelan AM; Calabrò ML; Gasperini P; Aversa SM; Zanchetta M; Meneghetti F; De Rossi A; Chieco-Bianchi L
J Natl Cancer Inst Monogr; 2001; (28):44-9. PubMed ID: 11158206
[TBL] [Abstract][Full Text] [Related]
11. Different impact of anti-retroviral regimen containing protease inhibitors on development of HIV-related Kaposi sarcoma.
Carleo MA; Di Martino F; Del Giudice A; Gargiulo M; Parrella G; Rosario P; Sangiovanni V; Viglietti R; Esposito V; Chirianni A
In Vivo; 2015; 29(1):133-6. PubMed ID: 25600542
[TBL] [Abstract][Full Text] [Related]
12. Resolution of severe Kaposi's sarcoma after initiation of antiretroviral triple therapy.
Jung C; Bogner JR; Goebel F
Eur J Med Res; 1998 Sep; 3(9):439-42. PubMed ID: 9737891
[TBL] [Abstract][Full Text] [Related]
13. Assessing the outcomes of HIV-infected persons receiving treatment for Kaposi sarcoma in Conakry-Guinea.
Bekolo CE; Soumah MM; Tiemtore OW; Diallo A; Yuma JD; Di Stefano L; Metcalf C; Cisse M
BMC Cancer; 2017 Dec; 17(1):806. PubMed ID: 29197357
[TBL] [Abstract][Full Text] [Related]
14. The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma.
Dupin N; Rubin De Cervens V; Gorin I; Calvez V; Pessis E; Grandadam M; Rabian C; Viard JP; Huraux JM; Escande JP
Br J Dermatol; 1999 May; 140(5):875-81. PubMed ID: 10354025
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodéficience humaine.
Dupont C; Vasseur E; Beauchet A; Aegerter P; Berthé H; de Truchis P; Zucman D; Rouveix E; Saiag P
AIDS; 2000 May; 14(8):987-93. PubMed ID: 10853980
[TBL] [Abstract][Full Text] [Related]
16. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma.
Portsmouth S; Stebbing J; Gill J; Mandalia S; Bower M; Nelson M; Bower M; Gazzard B
AIDS; 2003 Jul; 17(11):F17-22. PubMed ID: 12853764
[TBL] [Abstract][Full Text] [Related]
17. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
Martín-Carbonero L; Palacios R; Valencia E; Saballs P; Sirera G; Santos I; Baldobí F; Alegre M; Goyenechea A; Pedreira J; González del Castillo J; Martínez-Lacasa J; Ocampo A; Alsina M; Santos J; Podzamczer D; González-Lahoz J;
Clin Infect Dis; 2008 Aug; 47(3):410-7. PubMed ID: 18582203
[TBL] [Abstract][Full Text] [Related]
18. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma.
Bower M; Fox P; Fife K; Gill J; Nelson M; Gazzard B
AIDS; 1999 Oct; 13(15):2105-11. PubMed ID: 10546864
[TBL] [Abstract][Full Text] [Related]
19. Regression of AIDS-related Kaposi's sarcoma following combined antiretroviral treatment.
Monticelli A; Lewi D; Salomon H; Pampuro S; Libonatti O; Jauregui Rueda H; Hodara V
Rev Argent Microbiol; 2000; 32(4):206-8. PubMed ID: 11149154
[TBL] [Abstract][Full Text] [Related]
20. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
